A Randomized, Double-blinded, Multicenter Study of Denosumab Compared With Zoledronic acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer

INTERVENTION: Intervention name : Denosumab Dosage And administration of the intervention : Subcutaneous injection every 4 weeks Control intervention name : Zoledronic acid (Zometa) Dosage And administration of the control intervention : Intravenous infusion every 4 weeks CONDITION: Advanced breast cancer with bone metastases PRIMARY OUTCOME: Time to the first on‐study SRE SECONDARY OUTCOME: Time to the first‐and‐subsequent on‐study SRE INCLUSION CRITERIA: Adult with histologically or cytologically confirmed breast adenocarcinoma, and radiographic evidence of at least 1 bone metastasis